New Registry Data Shows Semaglutide Does Not Cause Pancreatic Cancer

Ozempic Users Worried About Pancreatic Cancer Get Reassuring Nordic Registry Data, but Follow-Up Lasted Under Two Years

A Novo-funded Nordic study of 97,464 semaglutide users found no rise in pancreatic cancer, but follow-up lasted under two years after a lag.

Semaglutide does not increase pancreatic cancer risk in large study

Semaglutide does not increase the risk of pancreatic cancer, according to an analysis of nearly 100,000 patients with type 2 diabetes. The findings were presented at the European Association for the Study of Diabetes (EASD) conference in Milan. Led by Einstein Karlstad of the Norwegian Institute of Public Health, the study compared patients using semaglutide against those treated with other standard glucose-lowering therapies, including insulin,…

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

Regulator-mandated study finds no link between semaglutide use and pancreatic cancer

New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry data from Denmark, Sweden and Norway. The regulator-mandated post-authorization study was presented by Anton Pottegård, a professor at the University of Southern Denmark in Odense, and colleagues.